RAPT Therapeutics, Inc. (RAPT)
NASDAQ: RAPT · IEX Real-Time Price · USD
7.93
-0.11 (-1.37%)
At close: Apr 18, 2024, 4:00 PM
8.09
+0.16 (2.02%)
Pre-market: Apr 19, 2024, 5:13 AM EDT
RAPT Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for RAPT Therapeutics stock have an average target of 22.29, with a low estimate of 10 and a high estimate of 40. The average target predicts an increase of 181.08% from the current stock price of 7.93.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for RAPT stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 3 | 1 | 1 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 12 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 10, 2024 |
| JP Morgan | JP Morgan | Hold Maintains $15 → $13 | Hold | Maintains | $15 → $13 | +63.93% | Mar 27, 2024 |
| UBS | UBS | Strong Buy → Hold Downgrades $61 → $10 | Strong Buy → Hold | Downgrades | $61 → $10 | +26.10% | Feb 22, 2024 |
| Barclays | Barclays | Buy Maintains $35 → $13 | Buy | Maintains | $35 → $13 | +63.93% | Feb 21, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $10 | Buy → Hold | Downgrades | $10 | +26.10% | Feb 21, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.29
from -3.05
EPS Next Year
-2.74
from -3.29
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 51.8M | 1.0B | 1.8B |
| Avg | n/a | n/a | 25.1M | 311.8M | 616.1M |
| Low | n/a | n/a | n/a | n/a | 119.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 3,960.8% | 480.2% |
| Avg | - | - | - | 1,140.1% | 97.6% |
| Low | - | - | - | - | -61.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.67 | -1.65 | -1.74 | 8.84 | 19.01 |
| Avg | -3.29 | -2.74 | -2.65 | 0.15 | 4.93 |
| Low | -3.57 | -3.62 | -3.00 | -6.73 | -5.46 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 12,902.3% |
| Avg | - | - | - | - | 3,275.2% |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.